VIKING THERAPEUTICS Aktie

>Aktienkurs

26.35 EUR -0.2% (TradegateBSX)

Ask: 26.65 EUR / 120 Stück

Bid: 26.6 EUR / 120 Stück

Tagesumsatz: 5003 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>Performance

1 Woche: -0,2%

1 Monat: -9,6%

3 Monate: +0,3%

6 Monate: -11,4%

1 Jahr: +7,4%

laufendes Jahr: -15,5%

>VIKING THERAPEUTICS Aktie

Name:

VIKING THERAPEUTICS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US92686J1060 / A12GD6

Symbol/ Ticker:

1VT (Frankfurt) / VKTX (NASDAQ)

Kürzel:

FRA:1VT, ETR:1VT, 1VT:GR, NASDAQ:VKTX

Index:

Webseite:

https://www.vikingtherape..

Profil:

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for metabolic and endocrine disorders. The company's lead program, VK2735, is a dual GLP-1/GIP receptor agonist currently in Phase 3 clinical..
>Volltext..

Marktkapitalisierung:

3091.11 Mio. EUR

Unternehmenswert:

2568.62 Mio. EUR

Umsatz:

EBITDA:

-432.31 Mio. EUR

Nettogewinn:

-407.09 Mio. EUR

Gewinn je Aktie:

-3.57 EUR

Schulden:

Liquide Mittel:

101.8 Mio. EUR

Operativer Cashflow:

Bargeldquote:

5.67

Umsatzwachstum:

Gewinnwachstum:

-244.89%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

VIKING THERAPEUTICS, VIKING THERAPEUTIC

Letzte Datenerhebung:

24.05.26

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 116.11 Mio. St.

Frei handelbar: 97.2%

Leerverk. Aktien: 19.51%

Rückkaufquote: -0.07%

Mitarbeiter: 53

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 209.91%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 7.07

PEG-Ratio: -0.03

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -64.04%

Eigenkaprendite: -70.04%

>Peer Group

Gesundheit, Lebererkrankungen & -behandlung/ Hepatitis, Stoffwechselerkrankungen (Diabetes/ Adipositas)

>Chart & Kurs - NASDAQ

>Alle News

23.05.26 - 23:00	Is Viking Therapeutics a Top Takeover Target? (Fool)
	Viking's strong obesity drug data continues fueling acquisition speculation....

21.05.26 - 14:48	Could Viking Therapeutics Be the Next Eli Lilly? (Fool)
	Demand for weight loss drugs may fuel growth for more than one player....

21.05.26 - 13:06	Viking Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
	SAN DIEGO, May 21, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the William Blair 46th......

19.05.26 - 03:12	Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics′ Pill Could Crash the Weight-Loss Party (Fool)
	This dark horse in the weight loss drug race is worth keeping on your watch list....

12.05.26 - 13:06	Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026 (PR Newswire)
	Oral VK2735 demonstrated early, progressive weight loss from Week 1 through Week 13 without a plateau Dose-dependent weight loss observed across all VK2735 cohorts, with the highest dose achieving a mean reduction of up to 12.2% (26.6 lbs) from baseline at Week 13 Baseline characteristics......

11.05.26 - 15:54	Viking Therapeutics: Nettoverlust im Q1 2026 durch hohe F&E-Kosten deutlich ausgeweitet (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

05.05.26 - 13:06	Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026 (PR Newswire)
	Poster Presentations Highlight Data from 13-Week Phase 2 VENTURE-Oral Trial of VK2735 and Participant Characteristics from Phase 3 VANQUISH-1 Trial of Subcutaneous VK2735 SAN DIEGO, May 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage......

04.05.26 - 22:12	Here′s Exactly Why Wall Street Thinks Viking Therapeutics Stock Could Soar 207% Over the Next 12 Months (Fool)
	The Street is bullish on this biotech's prospects, but is the sentiment justified?...

29.04.26 - 23:54	Viking Therapeutics: Höhere F&E-Ausgaben führen zu unerwartet hohem Quartalsverlust (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

29.04.26 - 22:12	Viking Therapeutics GAAP EPS of -$1.37 misses by $0.37 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

29.04.26 - 22:09	Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (PR Newswire)
	Conference call scheduled for 4:30 p.m. ET today -- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled -- -- Initiation of Phase 3 Oral VK2735 Trial for Obesity Expected 4Q26 -- -- VK2735 Maintenance Dosing Study Ongoing;......

22.04.26 - 22:39	Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026 (PR Newswire)
	Conference Call Scheduled for Wednesday, April 29 at 4:30 p.m. Eastern Time SAN DIEGO, April 22, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine......

21.04.26 - 16:00	Viking Therapeutics Gears Up for Q1 Earnings: Here′s What to Expect (Zacks)
	VKTX heads into Q1 earnings results with a focus on pipeline updates, as it expects no revenues and continued losses amid key obesity drug developments....

17.04.26 - 23:24	Better Long-Term Buy: Eli Lilly or Viking Therapeutics? (Fool)
	One is a behemoth, the other is a minnow, but both have promising opportunities in the GLP-1 space....

17.04.26 - 11:48	Is Viking Therapeutics the Ultimate Millionaire-Maker Obesity Stock for 2026? (Fool)
	The stock could have plenty of room to run from current levels....

15.04.26 - 01:00	Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider (Zacks)
	Viking Therapeutics, Inc. (VKTX) reached $35.52 at the closing of the latest trading day, reflecting a +1.46% change compared to its last close....

14.04.26 - 16:45	Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic? (Zacks)
	The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?...

14.04.26 - 01:45	Viking Therapeutics, Inc. (VKTX) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
	Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $35.01, signifying a +2.19% move from its prior day's close....

10.04.26 - 13:33	Viking Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
	SAN DIEGO, April 10, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will attend multiple upcoming......

07.04.26 - 01:00	Viking Therapeutics, Inc. (VKTX) Stock Dips While Market Gains: Key Facts (Zacks)
	The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $33.93, representing a -2.5% change from its previous close....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Ehrlich währt am längsten. Wer hat schon so viel Zeit? - Robert Lembke

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram